MARKET

AKRO

AKRO

Akero Therapeutics
NASDAQ
45.46
-0.23
-0.50%
After Hours: 44.00 -1.46 -3.21% 18:08 12/02 EST
OPEN
45.19
PREV CLOSE
45.69
HIGH
45.75
LOW
44.54
VOLUME
496.77K
TURNOVER
0
52 WEEK HIGH
48.24
52 WEEK LOW
7.52
MARKET CAP
2.13B
P/E (TTM)
-13.5028
1D
5D
1M
3M
1Y
5Y
Insider Sell: Akero Therapeutics
Insider Sell: Akero Therapeutics
MT Newswires · 11/14 17:41
Akero Therapeutics, Inc.'s (NASDAQ:AKRO) large institutional owners must be happy as stock continues to impress, up 5.6% over the past week
If you want to know who really controls Akero Therapeutics, Inc. ( NASDAQ:AKRO ), then you'll have to look at the...
Simply Wall St. · 11/13 12:46
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today an...
GlobeNewswire · 11/10 21:05
Morgan Stanley Maintains Equal-Weight on Akero Therapeutics, Raises Price Target to $40
Benzinga · 11/07 14:00
HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $64
Benzinga · 11/07 11:42
--Morgan Stanley Adjusts Price Target on Akero Therapeutics to $40 From $30, Maintains Equalweight Rating
--Morgan Stanley Adjusts Price Target on Akero Therapeutics to $40 From $30, Maintains Equalweight Rating
MT Newswires · 11/07 11:08
--HC Wainwright Adjusts Price Target on Akero Therapeutics to $64 From $62, Maintains Buy Rating
--HC Wainwright Adjusts Price Target on Akero Therapeutics to $64 From $62, Maintains Buy Rating
MT Newswires · 11/07 09:49
Recap: Akero Therapeutics Q3 Earnings
Benzinga · 11/04 14:07
More
About AKRO
Akero Therapeutics Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is a hormone that protects against cellular stress and regulates the metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase IIb clinical trials in patients with biopsy-confirmed NASH: the study in pre-cirrhotic patients with F2-F3 fibrosis and the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. Its EFX program is focused on patients with cirrhotic NASH (F4, compensated) in Phase IIb clinical trial.

Webull offers kinds of Akero Therapeutics Inc stock information, including NASDAQ:AKRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKRO stock methods without spending real money on the virtual paper trading platform.